Background
==========

The first 21 cases of clear cell sarcoma (CCS) of soft tissue, or malignant melanoma of soft parts, were reported in 1965 \[[@b1-medscimonit-25-6939]\]. Since then, worldwide, there have been reported individual cases and case series of clear cell sarcoma. CCS is a rare but distinct clinicopathologic entity, accounting for approximately 1% of all soft-tissue sarcomas \[[@b2-medscimonit-25-6939]\]. In 1983, Chung used the term, malignant melanoma of soft parts \[[@b3-medscimonit-25-6939]\] because of its clinical and histological similarities with malignant melanoma \[[@b4-medscimonit-25-6939]--[@b6-medscimonit-25-6939]\].

CCS usually presents in the deep soft tissue of the extremities, often adjacent to tendons, aponeuroses, or fascial structures. Most cases of CCS occur in adolescents and young adults. The histology of CCS shows nests of polygonal or fusiform cells, with groups of cells encased by delicate fibrous septa. Immunohistochemical staining shows positive staining for S-100 and HMB45. Despite their clinical and histological similarities, most CCS have a recurrent chromosomal translocation t(12;22) (q13;q12), which is associated with the EWS gene on chromosome 22q and the ATF1 gene on 12q. Recently, cyclic adenosine monophosphate responsive element binding protein 1 (CREB1) has been found in CCS but is not found in melanoma, which supports the distinction between the two tumor types.

Recently, several studies with small numbers of patients have reported 5-year survival rates ranging from 30--67% \[[@b7-medscimonit-25-6939]--[@b13-medscimonit-25-6939]\]. Due to the low incidence of the CCS and the limited sample size of previous studies, it is necessary to perform studies with larger study size to enhance the understanding of the behavior of CCS and to help diagnosis and prognosis. Therefore, this study used the Surveillance, Epidemiology, and End Results (SEER) database, which covers 30% of the entire US population, to accumulate a sufficient number of cases for investigation. The SEER database has been used extensively for studying rare cancers \[[@b14-medscimonit-25-6939]--[@b17-medscimonit-25-6939]\]. This population-based study aimed to identify prognostic factors that were linked to survival from CCS by analyzing demographic and actors associated with CCS that would be of clinical value.

Material and Methods
====================

Patient cohort
--------------

The Surveillance, Epidemiology, and End Results (SEER) is a free public cancer database. SEER collects data from 18 geographic registries, representing approximately 30% of the US population \[[@b18-medscimonit-25-6939]\]. We applied for an account to access data and to determine frequency rates. Inclusion criteria for this study included patients with a diagnosis of clear cell sarcoma (CCS) between 1973 and 2009, and a histological type according to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) code 9044. The primary site was selected as C49, and the location of the tumor was limited to the limbs and pelvis. There were 175 patients with CCS identified from the SEER database.

Ethical approval and consent to participate
-------------------------------------------

The clinical data used was from the SEER database, which is a public research resource, and patient consent and ethical approval for the study were not required.

Statistical analysis
--------------------

The incidence rates and clinical trends for CCS were analyzed using SEER\*Stat version 8.3.5 (National Cancer Institute, Bethesda, MD, USA). Incidence rates were age-adjusted to the 2000 US standard population. Annual percentage changes were calculated using the weighted least squared method. Demographic and clinical factors were analyzed using descriptive statistics, and the chi-squared test was used to calculate correlations between categorical variables. Cutoff values for tumor size were determined according to the area under the curve (AUC) ([Figure 1](#f1-medscimonit-25-6939){ref-type="fig"}). Kaplan-Meier curves were generated to assess disease-specific survival, and differences between groups were compared using log-rank analysis. Cox proportional hazard regression was performed on demographic, clinical, and treatment factors to estimate survival differences. Cox regression analysis was used for factors that had statistical significance in univariate analysis. We processed and analyzed the data using statistical software R (version 3.34, *<http://www.r-project.org>*). P\<0.05 indicated statistical significance.

Results
=======

Patient baseline characteristics
--------------------------------

A total of 257 patients with clear cell sarcoma (CCS) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. There were 82 patients who were excluded due to missing data. Finally, 175 patients were included in the study, and their characteristics are summarized in [Table 1](#t1-medscimonit-25-6939){ref-type="table"}.

Of the 175 patients with CCS, 98 patients (56.0%) were men, and 77 (44.0%) were women. Among patients with a given stage, 101 patients (57.71%) were diagnosed with localized CCS, 59 patients (33.71%) were diagnosed with regional CCS, and 15 patients (8.57%) were diagnosed with distant or metastatic CCS. The most common tumor location at diagnosis was the lower extremities, in 74.29% of cases. Tumor size was most commonly ≤3 cm at the time of diagnosis (44.57%). A total of 164 patients (93.71%) underwent surgical resection. Eighty patients (45.71%) underwent radiation therapy, and only 30 patients (17.14%) underwent chemotherapy for CCS.

Survival rate
-------------

In the 175 patients with CCS, the 5-year disease-specific survival was 62.9%, and the 10-year disease-specific survival was 51.3% ([Figure 2](#f2-medscimonit-25-6939){ref-type="fig"}). The population-adjusted incidence of CCS during the 35-year study period ranged from 0.006/100,000 in 1973 to 0.014/100,000 in 2009 ([Figure 3](#f3-medscimonit-25-6939){ref-type="fig"}). There was no significant difference in the annual percent change in incidence during the study period.

When stratified according to tumor size, we found that the 5-year disease-specific survival for patients with tumor size \>3 cm was lower (42.8%) than for patients with a tumor size ≤3 cm (86.2%; P\<0.0001). Also, 10-year disease-specific survival for patients with tumor size \>3 cm was much lower (26.4%) than for patients with a tumor size ≤3 cm (80.9%; P\<0.0001). The Kaplan-Meier survival curves by tumor size are shown in [Figure 4](#f4-medscimonit-25-6939){ref-type="fig"}.

When stratified according to tumor stage, we found that 5-year disease-specific survival for patients with a localized stage was much higher (82.4%) than for patients diagnosed at a regional stage (44%; P\<0.0001). The 10-year disease-specific survival for patients with a localized stage was much higher (68.8%) than for patients diagnosed at a regional stage (32.5%; P\<0.0001). None of the patients who were diagnosed at a distant stage survived for 5 years, and 2-year survival was 6.67%. The Kaplan-Meier survival curves by stage are shown in [Figure 5](#f5-medscimonit-25-6939){ref-type="fig"}.

Risk factors for survival
-------------------------

Data regarding age, race, gender, marital status, stage, tumor site, tumor size, surgery, radiation, and chemotherapy were included in univariate Cox regression analysis. We found that statistically significant prognostic factors for patients with CCS were race, gender, tumor stage, tumor size, chemotherapy, and surgery. Stage and tumor size were independent prognostic factors of survival in multivariate Cox regression analysis, but race, surgery, gender, and chemotherapy were not ([Table 2](#t2-medscimonit-25-6939){ref-type="table"}). Multivariate analysis showed a higher risk of death among patients with distant stage and regional stage (HR=22.22; 95% CI, 8.32--59.35; HR=3.25, 95% CI, 1.8--5.86, respectively), and patients with tumor size \>3 cm (HR=5.82; 95% CI, 2.83--12).

Discussion
==========

Clear cell sarcoma (CCS) of soft tissue, or malignant melanoma of soft parts, is a rare malignant sarcoma that accounts for approximately 1% of all soft tissue sarcomas \[[@b2-medscimonit-25-6939]\]. Although previous studies have reported general clinical characteristics of CCS \[[@b7-medscimonit-25-6939],[@b9-medscimonit-25-6939]--[@b12-medscimonit-25-6939],[@b19-medscimonit-25-6939],[@b20-medscimonit-25-6939]\], because of the rarity of the tumor, some of these previous studies have used the same cases. There are no studies with large sample sizes to verify these earlier findings. Currently, the most extensive study included 75 patients with CCS \[[@b19-medscimonit-25-6939]\]. To estimate the influence of various prognostic factors on survival, we used a large population-based sample. The population base of the Surveillance, Epidemiology, and End Results (SEER) database covers 30% of the entire US population and standardizes both classification and outcome criteria. These characteristics of SEER were was crucial to avoid potential selection bias and to collect sufficient numbers of patients for the study.

Previous studies have shown that the prognostic factors associated with CCS are tumor size \[[@b7-medscimonit-25-6939],[@b9-medscimonit-25-6939]--[@b13-medscimonit-25-6939],[@b19-medscimonit-25-6939]\], tumors site \[[@b12-medscimonit-25-6939]\], treatment \[[@b7-medscimonit-25-6939],[@b13-medscimonit-25-6939]\], and stage \[[@b13-medscimonit-25-6939],[@b21-medscimonit-25-6939]\]. However, only tumor size and stage were prognostic factors in the present study. However, to our knowledge, this study was the largest reported cohort of patients with CCS.

Similar to Blazer et al. \[[@b21-medscimonit-25-6939]\], we found that the majority of patients were diagnosed at an early or localized stage. The 5-year disease-specific survival was 62.9%, and 10-year disease-specific survival was 51.3%. More significantly, compared with patients with a localized stage, patients who were diagnosed with a regional stage had a 3.2-fold higher risk of death, and patients who were diagnosed with metastatic disease had a 22-fold higher risk of death.

CCS has been diagnosed mainly in young adults, and the age range at diagnosis has been reported to be between 20--40 years \[[@b22-medscimonit-25-6939],[@b23-medscimonit-25-6939]\], In a few rare cases, CCS may be diagnosed at extremes of age. The median age of the patients in our study was 41.28 years (range, 6--91 years). Although Kawai et al. \[[@b19-medscimonit-25-6939]\] reported that gender was an independent prognostic factor, previous studies found that gender was not an independent factor for prognosis of CCS \[[@b3-medscimonit-25-6939],[@b12-medscimonit-25-6939],[@b21-medscimonit-25-6939]\]. The findings of these previous studies are consistent with those of the present study.

The survival rate for CCS is not favorable in most studies. Takahira et al. reported that 5-year survival was 33.3% \[[@b24-medscimonit-25-6939]\]. Bianchi et al. reported that the 5-year survival rate was 56% \[[@b20-medscimonit-25-6939]\]. Deenik et al. reported that 5-year survival was 54% \[[@b7-medscimonit-25-6939]\]. Hocar et al. reported that 5-year survival was 59% \[[@b13-medscimonit-25-6939]\]. However, the 10-year survival rate dropped to 41%, and the 5-year survival rate was 70% for tumor size ≤5 cm, 46.8% for tumor size \>5 cm and 48.9% and 32% at 10 years, respectively \[[@b13-medscimonit-25-6939]\]. Lucas et al. reported that the 5-year survival rate was 67%, but the 10-year survival rate was 33%, and the 20-year survival rate was 10% \[[@b11-medscimonit-25-6939]\]. Ferrari et al. reported that the survival rate was 68.9% at 5 years and 66.4% at 10 years \[[@b12-medscimonit-25-6939]\]. In our study, the disease-specific survival was 62.9% at 5 years and 51.3% at 10 years. According to tumor size, disease-specific survivals were 86.2% for tumor size ≤3 cm and 42.8% for tumor size \>3 cm at 5 years and 80.9% for tumor size ≤3 cm and 26.4% for tumor size \>3 cm at 10 years, respectively. Therefore, most studies showed that the 5-year survival rate was \>50%, but the 10-year survival rate was relatively low. The findings of these studies are somewhat consistent with ours. The 5-year survival rate in previous studies was similar to our findings, but the 10-year survival rate in our study was much higher than previous findings. On multivariate analysis, tumor size was an independent risk factor (P\<0.01), which suggests that tumor size is negatively correlated with survival in CCS. These findings were consistent with those of previous studies.

In the present study, of 175 patients with CCS, 78 had a tumor size less than or equal to 3 cm, with a mean size of 4.6 cm (range 0.4--28 cm). Some studies found that tumor size was an independent prognostic factor for patients with CCS \[[@b7-medscimonit-25-6939],[@b11-medscimonit-25-6939]--[@b13-medscimonit-25-6939],[@b19-medscimonit-25-6939]\]. Kawai et al. found that tumor size \>5 cm had a poor prognosis and an increased incidence of local recurrence \[[@b19-medscimonit-25-6939]\]. Ferrari et al. reported that overall survival was substantially worse in patients with a tumor size \>5 cm \[[@b12-medscimonit-25-6939]\]. Finley et al. reported that patients with tumor size \>5 cm had a higher risk of metastasis \[[@b9-medscimonit-25-6939]\]. This finding may be partly explained by the fact that larger tumors take longer to develop and invade surrounding tissues such as blood vessels and lymph vessels to a greater extent.

Distant metastasis is regarded as a predictor of worse prognosis. Our findings support that patients with late-stage metastatic CCS have worse survival than those who are diagnosed at a local and regional stage. Patients with regional stage CCS had worse survival than those diagnosed at a local stage. Multivariate analysis showed that tumor stage was an independent prognostic factor in CCS.

Karita et al. reported five clear cell sarcoma patients who received treatment with doxorubicin, cisplatin, and caffeine, but only one patient had metastasis, and all five patients survived more than 5 years \[[@b25-medscimonit-25-6939]\]. Other studies reported that patients with CCS who received chemotherapy had a reduced risk of recurrence and metastases \[[@b26-medscimonit-25-6939],[@b27-medscimonit-25-6939]\]. However, most studies found that chemotherapy was ineffective \[[@b7-medscimonit-25-6939],[@b9-medscimonit-25-6939],[@b12-medscimonit-25-6939],[@b28-medscimonit-25-6939]\]. We also showed that chemotherapy appeared to be ineffective in CCS.

Univariate analysis showed that surgical treatment was a significant prognostic factor, while it was not an independent prognostic factor in multivariate analysis. This finding may be partly explained by the fact that patients with non-surgical treatment all had distant metastases, and the prognosis of these patients was even worse in our study.

This study had several limitations. The SEER database is a retrospective patient cohort that did not provide specific surgical information. Therefore, we could not study the impact of specific surgical treatments on patient prognosis. The current edition of the American Joint Committee on Cancer (AJCC) staging system does not include a code for patients with CCS diagnosed before 2004, and most patients did not have information on lymph node metastasis status. Therefore, we used the terms local, regional, and distant for staging CCS. Potential prognostic factors, such as biologic markers and tumor necrosis, were not included in the SEER information. Finally, the specifics of local recurrence, distant metastasis, and comorbidities that could influence treatment and outcomes were not available in SEER. Despite these limitations, we identified independent prognostic factors for survival for a rare soft tissue sarcoma that may assist clinicians in the assessment of prognosis and patient survival.

Conclusions
===========

This study used the Surveillance, Epidemiology, and End Results (SEER) database to study the largest reported cohort of patients with clear cell sarcoma (CCS). The findings indicated that prognostic factors were stage and tumor size. Local stage and tumor size ≤3 cm were favorable prognostic factors for survival in patients with CCS. Our findings may assist clinicians to evaluate patient prognosis for this rare form of soft tissue sarcoma.
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###### 

Descriptive demographic and clinical statistics of the study population with clear cell sarcoma (CCS).

  Characteristics            Number of cases   Valid % of total
  -------------------------- ----------------- ------------------
  Total number of patients   175               100.00
  Marital status                               
   Divorced                  14                8.00
   Married                   83                47.43
   Single                    71                40.57
   Widowed                   7                 4
  Age                                          
   ≤25                       43                24.57
   25 to 60                  104               59.43
   \>60                      28                16.00
  Sex                                          
   Female                    77                44.00
   Male                      98                56.00
  Race                                         
   Black                     25                14.29
   Other                     16                9.14
   White                     134               76.57
  Tumor site                                   
   Upper limb                45                25.71
   Lower limb                130               74.29
  Stage                                        
   Localized                 101               57.71
   Regional                  59                33.71
   Distant                   15                8.57
  Tumor size                                   
   ≤3                        78                44.57
   \>3                       97                55.43
  Surgery                                      
   Yes                       164               93.71
   No                        11                6.29
  Radiation                                    
   No                        95                54.29
   Yes                       80                45.71
  Chemotherapy                                 
   No                        145               82.86
   Yes                       30                17.14

###### 

Multivariable analysis results.

  Characteristics   Hazard ratio (95% CI)   P Value
  ----------------- ----------------------- ---------
  Sex                                       
   Female           Reference group         NA
   Male             0.76 (0.42--1.36)       0.352
  Race                                      
   Black            Reference group         NA
   Other            1.48 (0.56--3.95)       0.432
   White            0.59 (0.33--1.06)       0.079
  Stage                                     
   Localized        Reference group         NA
   Regional         3.25 (1.8--5.86)        \<0.001
   Distant          22.22 (8.32--59.35)     \<0.001
  Tumor size                                
   ≤3               Reference group         NA
   \>3              5.82 (2.83--12)         \<0.001
  Surgery                                   
   Yes              Reference group         NA
   No               0.99 (0.4--2.41)        0.979
  Chemotherapy                              
   No               Reference group         NA
   Yes              1.23 (0.63--2.3)        0.551

NA -- not applicable. CI -- confidence interval.
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